Kagan A, Gertler A, Ulman M, Bar-Khayim Y
Division of Nephrology, Kaplan Hospital, Rehovot, Israel.
Adv Perit Dial. 1991;7:247-52.
We studied the serum levels and peritoneal transport of prolactin in 13 CAPD patients and compared with 8 patients on hemodialysis and 10 normal subjects matched by age (30-78 years), sex, body mass index and serum glucose concentrations. CAPD and hemodialysis patients were matched also by hematocrit, serum creatinine, albumin concentrations and duration and dialysis (0-79 months), the prolactin levels in serum and in effluent were measured by RIA and NB2 bioassay. CAPD patients had higher serum prolactin levels than did hemodialysis-treated patients and control subjects. The bioactive/immunoactive ratio of serum prolactin in CAPD patients was 0.7 +/- 0.1 versus 0.9 +/- 0.1 in the control subjects (P less than 0.05) and 0.8 +/- 0.04 in the hemodialysis patients, mean +/- SEM. A significant linear correlation was demonstrated between serum levels and 8 hr peritoneal mass transfer of this hormone. A notable drop of prolactin took place after the first hour of dialysis. Serum prolactin was not influenced by peritoneal protein loss, glucose absorption rate or duration of CAPD. From this study we may conclude that hyperprolactinemia associated with CAPD is not affected by continuous peritoneal loss of prolactin, demonstrating only a slight decrease in bioactivity.
我们研究了13例持续性非卧床腹膜透析（CAPD）患者的血清催乳素水平及腹膜转运情况，并与8例血液透析患者及10名年龄（30 - 78岁）、性别、体重指数和血清葡萄糖浓度相匹配的正常受试者进行比较。CAPD患者和血液透析患者在血细胞比容、血清肌酐、白蛋白浓度以及透析时间（0 - 79个月）方面也相互匹配。采用放射免疫分析法（RIA）和NB2生物测定法测定血清及透析液中的催乳素水平。CAPD患者的血清催乳素水平高于接受血液透析治疗的患者及对照组受试者。CAPD患者血清催乳素的生物活性/免疫活性比值为0.7±0.1，而对照组受试者为0.9±0.1（P＜0.05），血液透析患者为0.8±0.04，均值±标准误。该激素的血清水平与8小时腹膜物质转运之间存在显著的线性相关性。透析第一小时后催乳素显著下降。血清催乳素不受腹膜蛋白丢失、葡萄糖吸收率或CAPD持续时间的影响。从本研究中我们可以得出结论，与CAPD相关的高催乳素血症不受催乳素持续腹膜丢失的影响，仅表现出生物活性略有下降。
